ZA917096B - Enzyme inhibitors - Google Patents

Enzyme inhibitors

Info

Publication number
ZA917096B
ZA917096B ZA917096A ZA917096A ZA917096B ZA 917096 B ZA917096 B ZA 917096B ZA 917096 A ZA917096 A ZA 917096A ZA 917096 A ZA917096 A ZA 917096A ZA 917096 B ZA917096 B ZA 917096B
Authority
ZA
South Africa
Prior art keywords
enzyme inhibitors
inhibitors
enzyme
Prior art date
Application number
ZA917096A
Other languages
English (en)
Inventor
Michael Szelke
Szelke Michael
David Michael Evans
Michael Evans David
David Michael Jones
Michael Jones David
Original Assignee
Ferring Peptide Research Partn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Peptide Research Partn filed Critical Ferring Peptide Research Partn
Publication of ZA917096B publication Critical patent/ZA917096B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0227—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the (partial) peptide sequence -Phe-His-NH-(X)2-C(=0)-, e.g. Renin-inhibitors with n = 2 - 6; for n > 6 see C07K5/06 - C07K5/10

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
ZA917096A 1990-09-07 1991-09-06 Enzyme inhibitors ZA917096B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909019558A GB9019558D0 (en) 1990-09-07 1990-09-07 Enzyme inhibitors

Publications (1)

Publication Number Publication Date
ZA917096B true ZA917096B (en) 1992-04-29

Family

ID=10681831

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA917096A ZA917096B (en) 1990-09-07 1991-09-06 Enzyme inhibitors

Country Status (13)

Country Link
EP (1) EP0652893A1 (xx)
JP (1) JPH06501461A (xx)
AU (1) AU8438791A (xx)
CA (1) CA2090858A1 (xx)
FI (1) FI930946A (xx)
GB (1) GB9019558D0 (xx)
HU (1) HUT64084A (xx)
IE (1) IE913120A1 (xx)
MC (1) MC2313A1 (xx)
NO (1) NO930731L (xx)
PT (1) PT98885A (xx)
WO (1) WO1992004371A1 (xx)
ZA (1) ZA917096B (xx)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9103612D0 (sv) * 1991-12-04 1991-12-04 Astra Ab New peptide derivatives
US5374623A (en) * 1992-08-20 1994-12-20 Prototek, Inc. Cysteine protease inhibitors effective for in vivo use
SE9301911D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptide derivatives
US6984627B1 (en) 1993-06-03 2006-01-10 Astrazeneca Ab Peptide derivatives
SE9301916D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
US5783563A (en) * 1993-06-03 1998-07-21 Astra Aktiebolag Method for treatment or prophylaxis of venous thrombosis
GB9318637D0 (en) * 1993-09-08 1993-10-27 Ferring Res Ltd Enzyme inhibitors
US5486623A (en) 1993-12-08 1996-01-23 Prototek, Inc. Cysteine protease inhibitors containing heterocyclic leaving groups
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
US6025472A (en) * 1994-12-21 2000-02-15 Corvas International, Inc. N-substituted glycine derivatives as enzyme inhibitors
US5696231A (en) * 1994-12-21 1997-12-09 Corvas International, Inc. N-substituted glycine derivatives as enzyme inhibitors
US6586466B2 (en) 1995-10-30 2003-07-01 Smithkline Beecham Corporation Carbohydrazide-protease inhibitors
KR19990067184A (ko) 1995-10-30 1999-08-16 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 프로테아제 억제제
AR005245A1 (es) 1995-12-21 1999-04-28 Astrazeneca Ab Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion
JP2003529528A (ja) 1998-04-24 2003-10-07 ３−ディメンショナル ファーマシューティカルズ， インコーポレイテッド プロテアーゼインヒビターとしてのアミノ酸アミジノヒドラゾン、アルコキシグアニジン、およびアミノグアニジン
YU42401A (sh) 1998-12-14 2003-12-31 Ortho-Mcneil Pharmaceuticals Inc. Supstituisani heterociklični acil-tripeptidi korisni kao modulatori receptora trombina
US20030144175A1 (en) 1998-12-23 2003-07-31 Smithkline Beecham Corporation Protease inhibitors
WO2000048623A1 (en) 1999-02-18 2000-08-24 Kaken Pharmaceutical Co., Ltd. Novel amide derivatives as growth hormone secretagogues
EP1232154A4 (en) 1999-11-10 2004-06-23 Smithkline Beecham Corp PROTEASE INHIBITORS
EP1232155A4 (en) 1999-11-10 2002-11-20 Smithkline Beecham Corp PROTEASE INHIBITORS
US6534498B1 (en) 1999-11-10 2003-03-18 Smithkline Beecham Corporation Protease inhibitors
JP2003527429A (ja) 2000-03-21 2003-09-16 スミスクライン・ビーチャム・コーポレイション プロテアーゼ阻害物質
GB0205527D0 (en) * 2002-03-08 2002-04-24 Ferring Bv Inhibitors
WO2004005318A2 (en) 2002-07-03 2004-01-15 Bio Science International, Inc. Peptides comprising aromatic d-amino acids and methods of use
FR2846969A1 (fr) * 2002-11-08 2004-05-14 Salles Jean Pierre Nouveaux vecteurs moleculaires amphiphiles fluorocarbones a usage biomedical et medical
EP1736465A4 (en) * 2004-03-31 2009-06-17 Ajinomoto Kk ANILINE DERIVATIVES
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB2494851A (en) 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
GB201212081D0 (en) 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph
IL239682B (en) 2013-01-08 2018-10-31 Kalvista Pharmaceuticals Ltd History of benzylamine and 2-(aminomethyl)pyridine
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
GB2510407A (en) 2013-02-04 2014-08-06 Kalvista Pharmaceuticals Ltd Aqueous suspensions of kallikrein inhibitors for parenteral administration
KR102276700B1 (ko) 2013-05-23 2021-07-12 칼비스타 파마슈티컬즈 리미티드 헤테로사이클릭 유도체
GB2517908A (en) 2013-08-14 2015-03-11 Kalvista Pharmaceuticals Ltd Bicyclic inhibitors
JP6527147B2 (ja) 2013-08-14 2019-06-05 カルヴィスタ ファーマシューティカルズ リミテッド 血漿カリクレインの阻害薬
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
AU2015328385B2 (en) 2014-10-06 2020-06-11 Lighthouse Pharmaceuticals, Inc. Inhibitors of lysine gingipain
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201421088D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
JP6877424B2 (ja) 2015-11-09 2021-05-26 コーテクシーミー， インコーポレイテッド アルギニンジンジパインの阻害剤
LT3464271T (lt) 2016-05-31 2020-09-10 Kalvista Pharmaceuticals Limited Pirazolo dariniai kaip plazmos kalikreino inhibitoriai
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
KR20190072530A (ko) 2016-09-16 2019-06-25 코텍자임, 인코포레이티드 리신 진지파인의 케톤 억제제
CN107011217B (zh) * 2017-03-24 2018-08-14 东华大学 一类脂溶性5-氨基酮戊酸衍生物及其制备方法和应用
CN107043338B (zh) * 2017-03-24 2018-09-25 东华大学 一类5-氨基酮戊酸衍生物及其制备方法和应用
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
IL274557B2 (en) 2017-11-29 2024-09-01 Kalvista Pharmaceuticals Ltd Dosage forms containing a plasma kallikrein inhibitor
GB201910116D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema
GB201910125D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of angioedema
EP4010333A1 (en) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
GB2591730A (en) 2019-12-09 2021-08-11 Kalvista Pharmaceuticals Ltd New polymorphs
GB201918994D0 (en) 2019-12-20 2020-02-05 Kalvista Pharmaceuticals Ltd Treatments of diabetic macular edema and impaired visual acuity
TW202228686A (zh) 2020-10-15 2022-08-01 英商卡爾維斯塔製藥有限公司 血管性水腫之治療
US20230381162A1 (en) 2020-10-23 2023-11-30 Kalvista Pharmaceuticals Limited Treatments of angioedema
US20240122909A1 (en) 2021-02-09 2024-04-18 Kalvista Pharmaceuticals Limited Treatments of hereditary angioedema
WO2023002219A1 (en) 2021-07-23 2023-01-26 Kalvista Pharmaceuticals Limited Treatments of hereditary angioedema
WO2023209381A1 (en) 2022-04-27 2023-11-02 Kalvista Pharmaceuticals Limited Formulations of a plasma kallikrein inhibitor
WO2024180100A1 (en) 2023-02-27 2024-09-06 Kalvista Pharmaceuticals Limited New solid form of a plasma kallikrein inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2964956D1 (en) * 1978-07-18 1983-04-07 Kabi Ab Bradykinin inhibiting tripeptide derivatives, process for their preparation and pharmaceutical preparations containing them
US4563305A (en) * 1981-01-07 1986-01-07 University Of Miami Radiolabelled substrates for assaying mammalian enzymes
US4835253A (en) * 1987-04-03 1989-05-30 The University Hospital Specific inhibitors of tissue kallikrein
ZA897514B (en) * 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors

Also Published As

Publication number Publication date
NO930731L (no) 1993-05-07
FI930946A (fi) 1993-04-26
GB9019558D0 (en) 1990-10-24
PT98885A (pt) 1992-08-31
IE913120A1 (en) 1992-03-11
CA2090858A1 (en) 1992-03-08
HUT64084A (en) 1993-11-29
JPH06501461A (ja) 1994-02-17
AU8438791A (en) 1992-03-30
EP0652893A1 (en) 1995-05-17
HU9300610D0 (en) 1993-05-28
MC2313A1 (fr) 1993-09-27
WO1992004371A1 (en) 1992-03-19
NO930731D0 (no) 1993-02-26
FI930946A0 (fi) 1993-03-03

Similar Documents

Publication Publication Date Title
GB9019558D0 (en) Enzyme inhibitors
IL108075A0 (en) Enzyme inhibitors
HU9303093D0 (en) Enzyme systhems
AU5533094A (en) Enzyme inhibitors
HU9202842D0 (en) Climotripsine-type proteases and inhibitors
AU660277B2 (en) 5-lipoxygenase inhibitors
GB9425701D0 (en) Enzyme inhibitors
ZA934970B (en) Enzyme inhibitors
GB9502985D0 (en) Enzyme inhibitors
GB9027268D0 (en) Lipolytic enzyme inhibitors
ZA918719B (en) Ester inhibitors
GB9212261D0 (en) Enzyme cloning
ZA939480B (en) Enzyme inhibitor
GB9018268D0 (en) Amylolytic enzyme
EP0543936A4 (en) Renin inhibitors
GB9007750D0 (en) Enzyme inhibitors
EP0464990A3 (en) New restriction enzyme
ZA949525B (en) Enzyme inhibitors
GB9012652D0 (en) Immobilized enzymes
KR100195376B1 (en) Haloethyl-substituted steroid enzyme inhibitors
ZA938867B (en) Enzyme inhibitors
GB9026251D0 (en) Netalloproteinase inhibitors
GB9324981D0 (en) Enzyme inhibitors
GB9319663D0 (en) Enzyme inhibitors
ZA914716B (en) Ace inhibitors